Mitobridge, Inc. logo

Mitobridge, Inc.

Mitobridge is dedicated to delivering therapeutics that improve mitochondrial function. Healthy mitochondria are vital to normal cellular activities. MItobridge (previously Mitokyne, Inc.), a biopharma company developing small molecule modulators that boost mitochondrial functions and provide treatments for mitochondrial genetic diseases, musculoskeletal & neurodegenerative disorders.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.mitobridge.com
Disease Focus
STOCK CODENon Listed
Address
1030 Massachusetts Avenue Suite 200, MA 02138
Cambridge
United States
Email
Contact Number

mitobridge

MItobridge (previously Mitokyne, Inc.), a biopharma company developing small molecule modulators that boost mitochondrial functions and provide treatments for mitochondrial genetic diseases, musculoskeletal & neurodegenerative disorders.

The company was founded in 2013 under the name Mitokyne to capitalize on the emerging biological understanding of how mitochondria function impacts health via bioenergetics, signaling, dynamics and biosynthesis.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/mitobridge-inc-” connections=”true” suffix=””]

Mitobridges MitoScreen_,a mitochondrial cross-screening matrix to assess different cellular responses to compounds, such as changes in gene expression, bioenergetics, biochemical-metabolic profile, and mitochondrial network morphology.

Nov 2017, Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement . Mitobridge will become a wholly-owned subsidiary of Astellas following the close of the acquisition.

In 2015, MItobridge entered into an agreement with the Salk Institute for Biological Sciences to access its intellectual property and technology related to Peroxisome Proliferator-Activated Receptor Delta (PPAR?).

In Oct 2013, Mitobridge granted Astellas an exclusive rights to develop and commercialize compounds that target mitochondrial function discovered using Mitokynes screening technology. Under the terms, Astellas has the exclusive right to acquire Mitokyne during the term of the five year agreement. Including upfront, R&D funding, acquisition and milestone payments, the total value of the partnership agreement could reach up to $730M.

In 2013, Mitokyne closed a $45 Mn series A equity financing from Astellas, MPM Capital, and Longwood Founders Fund.